Vidarabine

Vidarabine Overview

Vidarabine (chemically known as adenine arabinoside or ara-A; chemical formula C10H13N5O4) is a synthetic purine nucleoside analogue derived from Streptomyces antibioticus. Chemically, it belongs to the class of organic compounds known as purine nucleosides within the nucleosides and nucleotides superclass. Structurally, it consists of an adenine purine base linked to a D-arabinose sugar moiety instead of a standard D-ribose or D-deoxyribose sugar. The C-2′ hydroxyl stereochemistry inversion distinguishes Vidarabine from natural adenosine.

What Is Vidarabine and How Does It Work?

Vidarabine acts primarily through intracellular phosphorylation to ara-ATP, resulting in competitive inhibition of viral DNA polymerase and viral DNA chain termination.

Its primary chemical, physiological, and viral mechanisms include:

• Intracellular Triphosphorylation: Following cellular entry, Vidarabine is sequentially phosphorylated by cellular kinases (adenosine kinase and nucleoside diphosphate kinase) into its active triphosphate metabolite, adenine arabinoside triphosphate (ara-ATP). Unlike acyclovir, Vidarabine activation does not require initial viral thymidine kinase (TK) phosphorylation, preserving activity against TK-deficient HSV mutants.
• Competitive Inhibition of Viral DNA Polymerase: Ara-ATP acts as a direct competitive inhibitor of viral DNA polymerase with respect to its natural substrate, deoxyadenosine triphosphate (dATP).
• Incorporation & DNA Chain Termination: Viral DNA polymerase misincorporates ara-ATP into the growing viral DNA chain in place of adenosine. Once incorporated, the steric stereochemistry of the arabinose sugar disrupts viral DNA double-helix geometry, blocking further viral strand elongation and halting viral replication.
• Secondary Cellular Targets: Ara-ATP also inhibits ribonucleotide reductase and S-adenosylhomocysteine hydrolase, which contributes to minor cellular antimetabolite toxicity at high systemic concentrations.

Is Vidarabine FDA Approved?

Vidarabine was approved by the US FDA in November 1976 under the brand name Vira-A. Commercial manufacturing and distribution of US systemic and ophthalmic formulations were voluntarily discontinued as clinical utilization shifted toward safer and more effective alternatives like acyclovir and trifluridine. It remains available in specific international pharmacopeial markets (e.g., as Arasena-A in Japan).

What Was Vidarabine Used For?

• Treatment of acute keratoconjunctivitis and recurrent epithelial keratitis caused by Herpes Simplex Virus (HSV-1 and HSV-2).
• Historical intravenous treatment of Herpes Simplex Virus encephalitis.
• Historical intravenous treatment of severe Varicella-Zoster Virus (VZV / shingles and chickenpox) infections in immunocompromised patients.
• Historical treatment of neonatal HSV infection.

Before Receiving Vidarabine: Warnings & Precautions

Screen for severe hypersensitivity to Vidarabine, arabinofuranosyl purines, or formulation components. Systemic IV use carries severe warnings for central nervous system neurotoxicity (hallucinations, seizures, encephalopathy) and dose-dependent bone marrow suppression. Contraindicated with concurrent allopurinol therapy due to fatal metabolic toxicity, and avoided during pregnancy due to demonstrated teratogenicity and mutagenicity.

Clinical Safety Warnings

Vidarabine carries clinical safety warnings regarding Neurotoxicity, Bone Marrow Suppression, and Teratogenicity:

• Central Nervous System Neurotoxicity: Intravenous administration can induce tremors, hallucinations, ataxia, confusion, psychosis, seizures, and encephalopathy, particularly in patients with renal impairment.
• Myelosuppression: Dose-dependent leukopenia, megaloblastic anemia, and thrombocytopenia following systemic administration.
• Carcinogenicity & Mutagenicity: Demonstrated mutagenic, clastogenic, and carcinogenic potential in animal bioassays.

Who Should Not Receive Vidarabine?

• Individuals with a documented severe hypersensitivity (anaphylaxis) to Vidarabine, arabinofuranosyl purines, or formulation excipients.
• Patients receiving concurrent allopurinol therapy without dosage adjustments (allopurinol inhibits Vidarabine breakdown).
• Pregnant women (unless treating life-threatening HSV encephalitis with no alternative).

Vidarabine, Pregnancy & Lactation

Vidarabine is teratogenic and oncogenic in animal reproduction models at therapeutic doses, causing skeletal and visceral malformations. Vidarabine is classified as Pregnancy Category C and should be used during pregnancy only if the potential maternal benefit outweighs fetal risks. It is unknown whether Vidarabine is excreted in human breast milk; breastfeeding should be avoided during systemic therapy.

Tell Your Doctor Before Receiving Vidarabine

Inform your physician if you have a history of kidney disease, liver dysfunction, bone marrow suppression, neurological disorders, or are taking allopurinol.

Vidarabine Dosage & Administration

Topical ophthalmic dosing (3% ointment) is a 1/2-inch ribbon applied to the lower conjunctival sac 5 times daily at 3-hour intervals while awake, continuing for 7 days post-healing. Historical IV dosing for HSV encephalitis was 15 mg/kg/day as a slow continuous infusion over 12 to 22 hours daily for 10 to 14 days, with a 25% to 50% dose reduction in renal impairment.

Standard Historical Dosing Guidelines

• Topical Ophthalmic Dosing (3% Vira-A Ointment): Instill a 1/2-inch ribbon of 3% ointment into the lower conjunctival sac of the affected eye(s) 5 times daily at 3-hour intervals while awake. Continue for an additional 7 days after complete re-epithelialization to prevent viral recurrence.
• Intravenous Dosing (Historical HSV Encephalitis / VZV): 15 mg/kg/day administered as a slow continuous intravenous infusion over 12 to 22 hours daily for 10 to 14 days.
• Renal Impairment Dosing: Because Vidarabine’s primary metabolite (hypoxanthine arabinoside / ara-HX) is cleared renally, dosage reductions of 25% to 50% were required in patients with renal impairment (creatinine clearance less than 50 mL/min).

How Vidarabine Was Administered

• Ophthalmic Ointment: Wash hands before applying. Pull down lower eyelid, squeeze a 1/2-inch ribbon into the conjunctival sac, close eye gently, and blink. Avoid touching the tube tip to the eye or hands.
• Intravenous Infusion: Vidarabine is poorly soluble in aqueous fluids. Reconstitution required large volumes of intravenous infusion fluids (approx. 1,000 mL of fluid per 450 mg of drug) administered through an in-line filter over 12 to 22 hours.

Vidarabine Clinical Efficacy & Safety Profile

In the 1970s, clinical trials established Vidarabine as the first life-saving systemic antiviral therapy, reducing mortality in biopsy-proven HSV encephalitis from 70% down to 28%. In ophthalmic trials, 3% Vidarabine ointment achieved corneal ulcer healing in over 85% to 90% of HSV epithelial keratitis cases. However, comparative clinical trials in the 1980s demonstrated that acyclovir was significantly superior to Vidarabine in reducing HSV encephalitis mortality and morbidity, while offering superior aqueous solubility, lower volume requirements, and absence of severe neurotoxicity. Trifluridine similarly superseded Vidarabine in ophthalmic care.

Vidarabine Side Effects & Safety Profile

Phosphorylated host-side to ara-ATP to competitively inhibit viral DNA polymerase and terminate viral DNA chain elongation. Common side effects include localized ocular burning, lacrimation, nausea, vomiting, and anorexia. Serious risks include severe metabolic neurotoxicity (tremors, confusion, psychosis), leukopenia, megaloblastic anemia, and renal dysfunction. Voluntarily discontinued in the US in June 2001.

Common Side Effects

• Ophthalmic: Mild transient ocular burning, lacrimation, photophobia, conjunctival injection, and punctate keratitis.
• Systemic (IV): Nausea, vomiting, anorexia, diarrhea, epigastric distress, and weight loss.

Serious Adverse Events

• Central Nervous System Neurotoxicity: Tremors, muscle fasciculations, confusion, ataxia, hallucinations, psychosis, dizziness, seizures, and metabolic encephalopathy.
• Bone Marrow Suppression: Severe leukopenia, megaloblastic anemia, and thrombocytopenia.
• Severe Renal & Hepatic Toxicity: Elevated blood urea nitrogen (BUN), serum creatinine, and hyperbilirubinemia.
• Severe Hypersensitivity: Rare systemic allergic reactions and angioedema.

Managing Side Effects

For systemic therapy, perform baseline and daily complete blood counts (CBC) and renal function tests. If severe neurotoxicity or bone marrow depression occurs, discontinue IV Vidarabine immediately.

Vidarabine Drug Interactions & What to Avoid

Co-administration with allopurinol is strictly contraindicated because xanthine oxidase inhibition blocks ara-HX clearance, causing severe, toxic drug accumulation and fatal neurotoxicity. Combining with other myelosuppressive agents produces additive bone marrow suppression. Avoid alcohol during systemic therapy to limit CNS depression and hepatic strain.

Drug-Drug Interactions

• Allopurinol: Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting Vidarabine’s primary metabolite (ara-HX) to xanthine arabinoside. Co-administration decreases clearance, dramatically increasing serum ara-HX levels and causing severe neurotoxicity and bone marrow suppression.
• Other Myelosuppressive Drugs: Synergistic aggravation of neutropenia and anemia.

Food & Alcohol

Systemic food interactions are minimal. Avoid alcohol consumption during therapy to minimize central nervous system depression and liver strain.

Vidarabine Overdose, Emergency & Clearance

Deaminated rapidly by adenosine deaminase to hypoxanthine arabinoside (ara-HX), which is cleared renally with an elimination half-life of 3.5 to 4 hours (up to 20 hours in renal failure). Overdose causes acute neurotoxicity, seizures, and severe bone marrow failure managed with supportive care and hemodialysis, which efficiently removes ara-HX. Store 3% ophthalmic ointment at 15°C to 30°C, protected from excessive heat and freezing.

Elimination Kinetics & Overdose

Vidarabine has low oral bioavailability and must be given topically or intravenously. In the bloodstream, it is rapidly deaminated by systemic adenosine deaminase (ADA) to its principal metabolite, hypoxanthine arabinoside (ara-HX), which possesses weak antiviral activity (approx. 1/10th to 1/50th that of parent Vidarabine). Ara-HX is widely distributed into tissue fluids, including the central nervous system (CSF levels reach approx. 50% of concurrent plasma levels). It is excreted primarily by the kidneys (approx. 40% to 60% recovered in urine within 24 hours as ara-HX, with less than 3% as unchanged Vidarabine). The elimination half-life of parent Vidarabine is 1 hour, while the metabolite ara-HX has an elimination half-life of 3.5 to 4 hours (extending up to 20 hours in severe renal failure). Acute overdose causes severe neurotoxicity, seizures, and bone marrow shutdown. Treatment is supportive; hemodialysis efficiently removes the metabolite ara-HX.

Storage & Handling

Store 3% ophthalmic ointment at controlled room temperature between 15°C and 30°C (59°F to 86°F). Avoid excessive heat and freezing. Keep strictly out of reach of children.

Vidarabine Patient Management & Safety Protocols

Monitor corneal ulcer healing via slit-lamp examination during ophthalmic use. For systemic therapy, obtain daily complete blood counts and renal function tests while assessing daily for tremors, ataxia, or confusion. Ensure eye ointment application continues for 7 days after complete corneal re-epithelialization.

Clinical Monitoring Checklist

• Monitor corneal ulcer healing via slit-lamp examination during ophthalmic use.
• Baseline and daily Complete Blood Count (CBC) and renal function tests (serum creatinine, BUN) for IV therapy.
• Daily neurological evaluation for tremors, ataxia, or confusion.
• Verify that the patient is not taking allopurinol.

Key Do’s and Don’ts

• Do apply ophthalmic ointment at evenly spaced intervals as prescribed.
• Do continue eye therapy for 7 days after complete corneal healing.
• Do report vision changes, tremors, severe nausea, or confusion immediately.
• Do not touch the ointment tube tip to the eye or hands.
• Do not give IV formulations rapidly or in small fluid volumes due to poor drug solubility.
• Do not combine systemic Vidarabine with allopurinol without specialist dose adjustments.

Frequently Asked Questions

References

• DrugBank Database – Vidarabine Profile (DB00194)
• Classyfire Database – Purine Nucleosides Chemical Taxonomy Profile
• Official Product Monograph – Vira-A (Vidarabine Ophthalmic Ointment)

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.